Demographics of athlete participation relative to the Bethesda and ESC guidelines
| Against ESC but within Bethesda | Contrary to both ESC and Bethesda | p Value | |
|---|---|---|---|
| Number of patients | 70 | 60 | |
| Age at diagnosis (years) | 11±7 | 12±6 | NS |
| Sex (male/female) | 41/29 | 29/31 | NS |
| Average QTc (ms) | 444±23 | 501±46 | <0.0001 |
| Genotype | |||
| LQT1 | 41 (59%) | 33 (55%) | NS |
| LQT2 | 20 (29%) | 21 (35%) | NS |
| LQT3 | 8 (11%) | 3 (5%) | NS |
| Multiple | 1 (1%) | 3 (5%) | NS |
| History of symptoms | 1 (1%) | 28 (47%) | <0.0001 |
| β-Blockers | 55 (79%) | 57 (95%) | <0.008 |
| ICD | 0 | 20 (33%) | <0.0001 |
| Follow-up available (years) | 5.1±2.9 | 5.0±3.0 | NS |
Ages, QTc at diagnosis and follow-up are reported as mean±SD.
ESC, European Society of Cardiology; ICD, implantable cardioverter defibrillators; LQT, long QT.